Novavax Inc NVAX:NASDAQ

Last Price$109.15Cboe Real-Time Last Sale as of 2:20PM ET 7/13/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+14.79(15.67%)
Bid (Size)$109.22 (100)
Ask (Size)$109.59 (100)
Day Low / High$95.39 - 113.98
Volume6.1 M
 

View Biotechnology IndustryPeer Comparison as of 07/13/2020

 

Novavax Inc ( NASDAQ )

Price: $109.15
Change: +14.79 (15.67%)
Volume: 6.1 M
2:20PM ET 7/13/2020
 
 

Ultragenyx Pharmaceutical Inc ( NASDAQ )

Price: $85.95
Change: -0.31 (0.36%)
Volume: 186.0 K
2:22PM ET 7/13/2020
 
 

Acceleron Pharma Inc ( NASDAQ )

Price: $99.26
Change: -0.73 (0.73%)
Volume: 233.4 K
2:22PM ET 7/13/2020
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $116.32
Change: +1.39 (1.21%)
Volume: 193.2 K
2:22PM ET 7/13/2020
 
 

Allogene Therapeutics Inc ( NASDAQ )

Price: $42.80
Change: -0.02 (0.05%)
Volume: 250.4 K
2:20PM ET 7/13/2020
 

Read more news Recent News

2020 and 2021 Estimates for Novavax Targeted Higher but Q2 Earnings Number Falls
2:40AM ET 7/09/2020 MT Newswires

Earnings targets for Novavax Inc's (NASDAQ:NVAX, Recent Price: 98.30) Q2 ending June 30, 2020, and the full year forecasts for 2020 and 2021 have been...

Sector Update: Health Care Stocks Mixed in Late Trade
3:49PM ET 7/08/2020 MT Newswires

Health care stocks were mixed on Wednesday, with the NYSE Health Care Index up fractionally while the SPDR Health Care Select Sector ETF was down 0.1%. ...

Sector Update: Health Care Stocks Slipping Despite Small Rise for Biotech Shares
1:18PM ET 7/08/2020 MT Newswires

Health care stocks were losing ground in recent trade, with the NYSE Health Care Index declining 0.1% while the SPDR Health Care Select Sector ETF was down...

Analyst Actions: Ladenburg Thalmann Downgrades Novavax to Neutral From Buy, Lifts PT to $105 From $50
9:11AM ET 7/08/2020 MT Newswires

Novavax's (NVAX) average rating among analysts is a buy, with an average price target of $80. (MT Newswires covers equity, commodity and economic research...

View all Commentary and Analysis

Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
10:30AM ET 7/13/2020 Zacks

Is (NVAX) Outperforming Other Medical Stocks This Year?

Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
10:30AM ET 7/13/2020 Zacks

Is (NVAX) Outperforming Other Medical Stocks This Year?

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?
7:52AM ET 7/13/2020 Zacks

As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?
7:52AM ET 7/13/2020 Zacks

As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).

Company Profile

Business DescriptionNovavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD. View company web site for more details
Address20 Firstfield Road
Gaithersburg, Maryland 20878
Phone+1.240.268.2000
Number of Employees379
Recent SEC Filing07/10/20208-K
President, Chief Executive Officer & DirectorStanley C. Erck
Executive VP, Chief Financial & Business OfficerJohn J. Trizzino
President-Research & DevelopmentGregory M. Glenn
Chief Medical Officer & Senior Vice PresidentFilip Dubovsky

Company Highlights

Price Open$95.33
Previous Close$94.36
52 Week Range$3.54 - 113.98
Market Capitalization$6.3 B
Shares Outstanding58.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/05/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.15
Beta vs. S&P 500N/A
Revenue$34.3 M
Net Profit Margin-638.76%
Return on Equity78.82%

Analyst Ratings as of 07/07/2020

Buy
3
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset